World

Court upholds ‘Pharma Bro’ Martin Shkreli’s conviction

Associated Press
By Associated Press
2 Min Read July 18, 2019 | 6 years Ago
Go Ad-Free today

NEW YORK — A federal appeals court upheld the securities fraud conviction against former drug company CEO Martin Shkreli, known as “Pharma Bro,” on Thursday, along with a $7.3 million forfeiture of assets.

A judge sentenced Shkreli to seven years in prison last year for his conviction on charges he looted a drug company he founded, Retrophin, of $11 million in stock and cash to pay back investors in two failed hedge funds he ran.

“We are obviously disappointed with the court’s decision,” attorney Benjamin Brafman said in an emailed statement.

At the trial in federal court in Brooklyn, investors took to the witness stand to accuse him of keeping them in the dark about huge losses as his scheme unfolded. The defense argued there wasn’t any harm done because in the end all of them got rich off Retrophin stock.

Before his arrest, Shkreli was best known for buying the rights to a lifesaving drug at another company in 2014 and promptly raising the price from $13.50 to $750 per pill.

He also gained notoriety for attacking critics on social media as Pharma Bro and for being barred from Twitter for posts about a female journalist.

He also offered a $5,000 bounty on Facebook for a strand of Hillary Clinton’s hair. Defense attorneys called the post political satire, but the judge wasn’t amused, saying there was a risk it could be taken seriously by fellow Clinton detractors.

Share

Categories:

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options